Spatial navigation in preclinical Alzheimer's disease: A review

A research consortium led by Antoine Coutrot has published a comprehensive review in arXiv analyzing spatial navigation as a sensitive cognitive marker for preclinical Alzheimer's disease. The paper synthesizes evidence from nine studies showing that specific navigation tasks—particularly path integration (tracking one's position while moving) and wayfinding (navigating to remembered locations)—correlate strongly with established Alzheimer's biomarkers like phosphorylated tau (p-tau) in cerebrospinal fluid and plasma. This correlation exists even in cognitively unimpaired individuals, suggesting navigation deficits emerge during the prolonged preclinical phase when neuropathology accumulates but before memory symptoms appear.

The researchers explain that spatial navigation relies heavily on neural circuits in the medial temporal lobe—the same brain regions where Alzheimer's pathology first develops. Unlike episodic memory tests that typically detect impairment only after substantial brain damage, navigation tasks appear sensitive to earlier, subtler changes. The review highlights how virtual reality navigation assessments could provide a scalable, non-invasive screening approach, potentially identifying at-risk individuals 10-15 years before clinical diagnosis. This early detection window could enable timely interventions aimed at mitigating future cognitive decline.

Future research directions include standardizing navigation assessment protocols and validating these digital biomarkers in larger, diverse populations. The team emphasizes that combining navigation performance with fluid biomarkers could create more accurate risk stratification tools. As digital health technologies advance, spatial navigation testing represents a promising bridge between neuroscience research and practical clinical applications for Alzheimer's prevention.